From: Inflammatory profile in LRRK2-associated prodromal and clinical PD
 | Female N = 152 | Male N = 96 | Female | Male | ||
---|---|---|---|---|---|---|
 | NMCLRRK2 N = 63 | CON N = 89 | NMCLRRK2 N = 52 | CON N = 44 | p value NMCLRRK2 CON | p value NMCLRRK2 CON |
Age Years | 51 23–84 | 57 18–83 | 54 27–82 | 58 28–83 | 0.087 | 0.110 |
UPDRS-III | 0 0–13 | 0 0–9 | 0 0–15 | 0 0–8 | 0.021 | 0.542 |
MoCA | 28 18–30 | 27 17–30 | 27 18–30 | 27 17–30 | 0.756 | 0.809 |
RBD Questionnaire | 1 0–9 | 1 0–13 | 2 0–9 | 1 0–11 | 0.396 | 0.943 |
ESS | 6 0–15 | 6 0–15 | 5 0–15 | 6 0–14 | 0.948 | 0.399 |
SCOPA-AUT | 8 1–33 | 7 0–41 | 7 0–39 | 6 0–30 | 0.221 | 0.729 |
Regular anti-inflammatory medication (% of individuals) | 3.7 | 1.2 | 4.6 | 0.0 | 0.561 | 0.495 |